PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Pfizer (PFE) PT Raised to $42 at Deutsche Bank Following 4Q
January 31, 2018 7:39 AM ESTDeutsche Bank raised its price target on Pfizer (NYSE: PFE) to $42.00 (from $41.00) while maintaining a Buy rating following 4Q. PFE reported 4Q EPS of $0.62, well above consensus of $0.56. Revenue came in just above estimates, while gross margin was lower and operating expenses were... More
Pfizer (PFE) Tops Q4 EPS by 6c, FY18 EPS Guidance Beats, Sees $15B Repatriation Tax Liability
January 30, 2018 6:46 AM EST(Updated - January 30, 2018 6:49 AM EST)
Pfizer (NYSE: PFE) reported Q4 EPS of $0.62, $0.06 better than the analyst estimate of $0.56. Revenue for the quarter came in at $13.7 billion versus the consensus estimate of $13.68 billion.
Pfizers 2018 financial guidance is presented below. Financial guidance reflects... More
